Aloke Finn

Interventional cardiologist / Cardiologist
CVPath Institute - Gaithersburg, United States of America

Latest contributions

Preventing distal particles embolization after DCB angioplasty

21 May 2025 – From EuroPCR 2025

At EuroPCR 2025, Aloke Finn and Antonio Colombo share their insights on a specific and often overlooked complication of drug-coated balloon (DCB) angioplasty: particulate embolization.

They begin by clarifying the distinction between this phenomenon and traditional distal embolization, explaining that particulate embolization is iatrogenic and device-related—it is...

Preventing distal particles embolization after DCB angioplasty

Treating complex CAD indications with sirolimus coated balloon: evidence and performance

22 May 2025 – From EuroPCR 2025

Gain a deeper understanding of how sirolimus coated balloon (SCB) technology is shaping the treatment of complex coronary artery disease (CAD). This EuroPCR 2025 session brings together compelling clinical trial data and real-world case presentations to illustrate the safety, efficacy, and versatility of the MagicTouch SCB...

Treating complex CAD indications with sirolimus coated balloon: evidence and performance

Transforming PCI: mastering the implementation of drug-eluting balloons

22 May 2025 – From EuroPCR 2025

This EuroPCR 2025 session provides a comprehensive overview of drug-eluting balloons (DEBs) and their growing role in percutaneous coronary intervention (PCI). Gain a clear understanding of the clinical evidence and rationale supporting DEBs, including how these devices minimize metal implantation and effectively treat both standard and...

Transforming PCI: mastering the implementation of drug-eluting balloons

The ARC consensus on DCB - evidence-based DCB technology

15 May 2024 – From EuroPCR 2024

In this replay, discover why DCBs are essential in treating de novo CAD, the importance of optimal lesion preparation for long-term success, and how future trials will focus on treatment strategies rather than device comparisons, highlighting the need for further research.

Evidence-based on DCB technology that have dictated the ARC consensus on DCB

Sirolimus-coated balloon: expanding the scope of indications for complex coronary artery disease treatment

14 May 2024 – From EuroPCR 2024

Watch this session to gain case-based insights on using DCBs in complex settings. Learn valuable tips and tricks for optimal DCB application, including the best timing and situations for their use. Discover how to effectively implement a hybrid strategy that combines DES and DCB when needed.

Sirolimus-coated balloon: expanding the scope of indications for complex coronary artery disease treatment

Sirolimus coated balloon and coronary artery disease: expanding the treatment indications

17 May 2022 – From EuroPCR 2022

Through a case presentation, as well as upcoming studies and rationale for the Food and Drug Administration, the aim of this EuroPCR 2022 session is to help you answer the following questions: how can the use of a sirolimus-coated DCB be expanded in new and challenging treatment indications? Why is...

Sirolimus coated balloon and coronary artery disease: expanding the treatment indications

MagicTouch sirolimus coated balloon continues to be the choice of treatment for CAD

19 May 2021 – From EuroPCR 2021

Watch this session presented by Antonio Colombo, Aloke Finn, Sandeep Basavarajaiah, Gianluca Caiazzo and Bernardo Cortese in order to know where to use a DCB in today's clinical practice, to learn about real-world case-based experience and interesting data presentation from various registries and clinical studies, and to understand the technology...

MagicTouch sirolimus coated balloon continues to be the choice of treatment for CAD